# Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

> **NCT00498914** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 41 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Diffuse
- Lymphoma, B-Cell Refractory

## Interventions

- **DRUG:** YM155

## Key facts

- **NCT ID:** NCT00498914
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Futility boundary at interim analysis not met
- **Last updated:** 2015-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498914, "Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00498914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*